Skip to main content

Neurotoxicity

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
2 programs
2
duloxetine hydrochloridePhase 31 trial
lamotriginePhase 31 trial
Active Trials
NCT00489411Completed231Est. Mar 2013
NCT00068445Completed131Est. Nov 2013
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
monosialogangliosidePhase 21 trial
Active Trials
NCT02500810Unknown106Est. Dec 2018
Veloxis Pharmaceuticals
1 program
EnvarsusPHASE_41 trial
Active Trials
NCT03823768Completed30Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Veloxis PharmaceuticalsEnvarsus
Alliance Pharmaceuticalsduloxetine hydrochloride
Alliance Pharmaceuticalslamotrigine
UNION therapeuticsmonosialoganglioside

Clinical Trials (4)

Total enrollment: 498 patients across 4 trials

NCT03823768Veloxis PharmaceuticalsEnvarsus

Envarsus Neurotoxicity Burden in Liver Transplant Patients

Start: Jan 2020Est. completion: Jan 202430 patients
Phase 4Completed
NCT00489411Alliance Pharmaceuticalsduloxetine hydrochloride

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Start: Apr 2008Est. completion: Mar 2013231 patients
Phase 3Completed
NCT00068445Alliance Pharmaceuticalslamotrigine

Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Start: Feb 2004Est. completion: Nov 2013131 patients
Phase 3Completed
NCT02500810UNION therapeuticsmonosialoganglioside

Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients

Start: Jul 2015Est. completion: Dec 2018106 patients
Phase 2Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.